Literature DB >> 29211912

Intestinal T Cell Profiling in Inflammatory Bowel Disease: Linking T Cell Subsets to Disease Activity and Disease Course.

Carolijn Smids1, Carmen S Horjus Talabur Horje1, Julia Drylewicz2, Britt Roosenboom1, Marcel J M Groenen1, Elly van Koolwijk3, Ellen G van Lochem3, Peter J Wahab1.   

Abstract

INTRODUCTION: A dysregulated intestinal T cell response is presumed in patients with inflammatory bowel disease [IBD]. In this longitudinal study, we investigated the changes in intestinal T lymphocyte subsets in IBD at first presentation and over time during endoscopic active or inactive disease, and relate them to disease activity and outcome.
METHODS: We included 129 newly diagnosed patients (87 Crohn's disease [CD], 42 ulcerative colitis [UC]) and 19 healthy controls [HC]. Follow-up biopsy specimens were analysed from 70 IBD patients. Immunophenotyping of specimens was performed by flow cytometry identifying lymphocyte subpopulations.
RESULTS: IBD patients at diagnosis displayed higher percentages of CD4 T+ cells, Tregs, and central memory T cells [TCM] and with lower percentages of CD8 and CD103 T lymphocytes than HC. Follow-up specimens of patients with endoscopic inactive disease showed T cell subset recovery comparable to HC. Endoscopic active disease at follow-up coincided with T cell subsets similar to those at diagnosis. In UC, lower baseline percentages of CD3 cells was associated with milder disease course without the need of an immunomodulator, whereas in CD, higher baseline percentages of CD4 and Tregs were associated with complicated disease course.
CONCLUSIONS: The intestinal T cell infiltrate in IBD patients with active endoscopic disease is composed of increased percentages of CD4+ T cells, Tregs, and TCM, with lower percentages of CD8+ T cells and CD103+ T cells, compared with HC and endoscopic inactive IBD. Baseline percentages of CD3, CD4, and Tregs were associated with disease outcome. Further research is needed to demonstrate the predictive value of these lymphocyte subsets.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29211912     DOI: 10.1093/ecco-jcc/jjx160

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  29 in total

1.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

Review 2.  Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.

Authors:  Jie Wang; Idan Goren; Bo Yang; Sinan Lin; Jiannan Li; Michael Elias; Claudio Fiocchi; Florian Rieder
Journal:  Aliment Pharmacol Ther       Date:  2021-12-21       Impact factor: 8.171

3.  The Prevalence of Autoimmune Diseases in Patients with Primary Open-Angle Glaucoma Undergoing Ophthalmic Surgeries.

Authors:  Maltish M Lorenzo; Julia Devlin; Chhavi Saini; Kin-Sang Cho; Eleftherios I Paschalis; Dong Feng Chen; Rafaella Nascimento E Silva; Sherleen H Chen; Milica A Margeta; Courtney Ondeck; David Solá-Del Valle; James Chodosh; Joseph B Ciolino; Roberto Pineda; Louis R Pasquale; Lucy Q Shen
Journal:  Ophthalmol Glaucoma       Date:  2021-08-18

4.  Cannabinoid Receptor 2 (CB2) Inverse Agonist SMM-189 Induces Expression of Endogenous CB2 and Protein Kinase A That Differentially Modulates the Immune Response and Suppresses Experimental Colitis.

Authors:  Sonia Kiran; Ahmed Rakib; Bob M Moore; Udai P Singh
Journal:  Pharmaceutics       Date:  2022-04-26       Impact factor: 6.525

Review 5.  Human gut-associated lymphoid tissues (GALT); diversity, structure, and function.

Authors:  Urs M Mörbe; Peter B Jørgensen; Thomas M Fenton; Nicole von Burg; Lene B Riis; Jo Spencer; William W Agace
Journal:  Mucosal Immunol       Date:  2021-03-22       Impact factor: 7.313

6.  Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis.

Authors:  Padhmanand Sudhakar; Bram Verstockt; Jonathan Cremer; Sare Verstockt; João Sabino; Marc Ferrante; Séverine Vermeire
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325

7.  Protein kinase 2 (CK2) controls CD4+ T cell effector function in the pathogenesis of colitis.

Authors:  Wei Yang; Sara A Gibson; Zhaoqi Yan; Hairong Wei; Jiahui Tao; Bingdong Sha; Hongwei Qin; Etty N Benveniste
Journal:  Mucosal Immunol       Date:  2020-01-27       Impact factor: 7.313

8.  Identification of Immune Cell Landscape and Construction of a Novel Diagnostic Nomogram for Crohn's Disease.

Authors:  Hong Chen; Chunqiu Chen; Xiaoqi Yuan; Weiwei Xu; Mu-Qing Yang; Qiwei Li; Zhenyu Shen; Lu Yin
Journal:  Front Genet       Date:  2020-04-29       Impact factor: 4.599

9.  Aucuboside Inhibits the Generation of Th17 Cells in Mice Colitis.

Authors:  Chenxue Mei; Xiao Wang; Fanxiang Meng; Xiaoqing Zhang; Ling Chen; Siqi Yan; Junxiu Xue; Xun Sun; Yuanyuan Wang
Journal:  Front Pharmacol       Date:  2021-07-16       Impact factor: 5.810

10.  Decitabine attenuates dextran sodium sulfate‑induced ulcerative colitis through regulation of immune regulatory cells and intestinal barrier.

Authors:  Chang Su; Shaoqun Liu; Xiaoying Ma; Xiaotong Yang; Jianwen Liu; Peiyong Zheng; Yiou Cao
Journal:  Int J Mol Med       Date:  2020-05-18       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.